

Towards artificial tissue models: past, present, and future of 3D bioprinting

This content has been downloaded from IOPscience. Please scroll down to see the full text.

2016 Biofabrication 8 014103

(<http://iopscience.iop.org/1758-5090/8/1/014103>)

View [the table of contents for this issue](#), or go to the [journal homepage](#) for more

Download details:

IP Address: 171.66.209.4

This content was downloaded on 01/03/2016 at 19:19

Please note that [terms and conditions apply](#).

Biofabrication



PAPER

Towards artificial tissue models: past, present, and future of 3D bioprinting

RECEIVED
2 May 2015

REVISED
12 October 2015

ACCEPTED FOR PUBLICATION
5 November 2015

PUBLISHED
1 March 2016

Ahu Arslan-Yildiz¹, Rami El Assal¹, Pu Chen, Sinan Guven, Fatih Inci and Utkan Demirci²

Bio-Acoustic-MEMS in Medicine (BAMM) Laboratory, Canary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford School of Medicine, Palo Alto, CA 94304, USA

¹ These authors contributed equally to this study.

² Author to whom any correspondence should be addressed.

E-mail: utkan@stanford.edu

Keywords: bioprinting, 3D printing, biomaterials, artificial tissue, biofabrication, tissue engineering, regenerative medicine

Abstract

Regenerative medicine and tissue engineering have seen unprecedented growth in the past decade, driving the field of artificial tissue models towards a revolution in future medicine. Major progress has been achieved through the development of innovative biomanufacturing strategies to pattern and assemble cells and extracellular matrix (ECM) in three-dimensions (3D) to create functional tissue constructs. Bioprinting has emerged as a promising 3D biomanufacturing technology, enabling precise control over spatial and temporal distribution of cells and ECM. Bioprinting technology can be used to engineer artificial tissues and organs by producing scaffolds with controlled spatial heterogeneity of physical properties, cellular composition, and ECM organization. This innovative approach is increasingly utilized in biomedicine, and has potential to create artificial functional constructs for drug screening and toxicology research, as well as tissue and organ transplantation. Herein, we review the recent advances in bioprinting technologies and discuss current markets, approaches, and biomedical applications. We also present current challenges and provide future directions for bioprinting research.

1. Introduction

When the printing press was first introduced in the 15th century [1], it offered a high-throughput tool to rapidly replicate and widely spread information at a low cost. This approach broke the barriers to free-thinking and gave access to massive amounts of information enabling innovation at an unprecedented rate [2, 3]. Although there have been other revolutionary breakthroughs that enable information transfer since then, the role of printing as a nucleating invention is still significant. Analogously, bioprinting can potentially enable a high-throughput and affordable tool to assemble cells, enabling complex tissue constructs to become broadly available to many researchers and scientists [2–4]. Bioprinting is the process of patterning biological materials (e.g., cells, biomaterials, and biomolecules) to fabricate tissue-mimicking constructs using advanced additive manufacturing technologies [5–8]. During the bioprinting process, biocompatible materials (i.e., bio-inks) are

used to facilitate the printing and act as matrices (i.e., bio-papers) for printed cells [5, 9, 10], which can then be grown in perfusion vessels (i.e., bioreactors) for further cellular and functional maturation.

As tissue engineering advances, innovative tools targeting new biological and medical challenges are becoming available. For instance, bioprinting has the potential to create tissue constructs addressing the needs for regenerative and transplantation medicine [11]. Furthermore, bioprinting technologies enable precise fabrication of three-dimensions (3D) heterogeneous functional units for regenerative and developmental biology [12]. In addition, there is evidence that bioprinting might lead to applications for precision medicine mimicking the complexity of native tissues [13, 14]. Translation of bio-inspired materials and their applications in 3D bioprinting aims to yield cellular and extracellular constituents of tissues by mimicking specific functions and structures in cells [15]. For instance, tissue engineering and regenerative medicine promises to create new tissue constructs that

address the need for model systems in drug screening and precision medicine applications [16]. Therefore, as the bioprinting technology arena progresses, more biomedical applications are expected to emerge [15].

Ultimately, bioprinting technology will provide inspiring solutions to address current challenges in tissue engineering and regenerative medicine [17] by utilizing basic science, materials science [18, 19], and robotics [20–22]. Herein, we review the recent technological advances in biomanufacturing focusing on 3D bioprinting platforms for tissue engineering and regenerative medicine. We also highlight the current market, approaches, and biomedical applications of bioprinting as well as provide a future direction for bioprinting research.

2. Bioprinting industry

3D bioprinting is experiencing a rapid transformation from basic research in academic laboratories to an emerging industry due to its potential commercial value in broad fields including pharmaceutical discovery, precision medicine, and tissue transplantation [11, 23, 24]. The market size of 3D printing was approximately \$2.2 billion in 2012, and it is expected to reach \$10.8 billion by 2021 [25]. In 2014, there were more than 30 companies worldwide having a business directly related to 3D bioprinting and bioprinted products. Products and services provided by these companies are focused on 3D bioprinters and bioprinted scaffolds. Over seven types of 3D bioprinters are available in the market, which target research and development (R&D) users in both academic institutions and biotechnology/biomedical companies (table 1). These bioprinters are mainly based on two types of printing technologies: droplet and extrusion bioprinting. *Tissue Regeneration Systems* provides patient-customized solution to repair skeletal defects and damages using bioprinted polycaprolactone (PCL) scaffolds [26]. The Food and Drug Administration (FDA) has approved this solution in 2013 as the first 3D bioprinted implant for skeletal reconstruction and bone regeneration. In addition, *Organovo* announced the exVive3D™ Liver in 2014 [27]. These bioprinted human liver tissue mimics were maintained functionally and designed to provide drug testing service to evaluate drug toxicity [28]. Although it offers preclinical *in vitro* drug screening service, a reliable, fully functional, and commercially available liver tissue has not been achieved due to many biological and technological challenges that need to be overcome in the liver tissue engineering field [29]. 3D bioprinting companies, their products, and current projects are listed in table 2. Some bioprinting companies also provide professional commercial softwares (e.g., TSIM®, BioAssemblyBot®, and BioCAD®) to design, draw, and print multiscale structures ranging from cells to tissue constructs.

3. State of art bioprinting technologies and materials

3.1. Bioprinting strategies

The 3D printing of biological materials (i.e., cells, growth factors, and hydrogels) is based on three major strategies: laser [30–32], droplet [33–38], and extrusion [39–44] based bioprinting (figure 1). Each strategy provides certain features that influence the printing outcomes including cell viability and functionality post-printing [2–5, 45]. In this section, we discuss in more detail the mechanisms and parameters of bioprinting techniques (table 3).

3.1.1. Droplet bioprinting

The droplet bioprinter (also referred as drop-by-drop or drop-on-demand bioprinter) is one of the earliest used printing methods in the field of tissue and organ biofabrication [46]. This approach utilizes a non-contact reprographic strategy, where the droplet encapsulated cells and nonliving materials are printed and patterned layer-by-layer on a substrate [23, 47]. The droplet bioprinters can be divided according to the mechanism used to generate the droplets: thermal [3, 33, 48, 49] or piezoelectric (acoustic) [2, 37, 38, 50] modalities (figure 1(a)). Thermal droplet bioprinting function by generating heat within the bio-ink chamber, which results in pulses of pressure that eject picoliter volume droplets at the printer orifice [33]. While the piezoelectric bioprinter utilizes a piezoelectric crystal actuator to generate acoustic waves within the bio-ink chamber that expel the droplets through the printer nozzle. The use of droplet bioprinters has tremendously increased during recent years due to relatively low cost, microscale precision, high printing speed (10 kHz), high cell viability post-printing, and compatibility with nonliving printing materials (e.g., hydrogels) [17, 37, 51]. However, certain drawbacks have hampered its use in tissue biofabrication such as difficulty of printing high viscosity materials (>10 centipoise) and high cell densities (>10 million cells/ml) without resulting in clogging of the printer ejector [5, 52–54]. In addition, the mechanical properties of printed structures are vulnerable due to use of low viscosity bio-inks, which in turn impedes the creation of fully functional 3D constructs [11, 55].

3.1.2. Laser bioprinting

Based on the laser-induced forward transfer method, laser bioprinting has been also utilized for patterning live cells and biofabrication of tissues [56, 57]. In this approach, the cells are printed using a laser beam pulsating at controlled duration of time [58]. The device is composed of a laser beam focused on a ribbon (a glass side which is coated with a laser-absorbing layer made of titanium, gold, or polyimide membrane), where the cells and biological materials are excited and collected on substrate, which is facing the

Table 1. Comparison of 3D bioprinters.

Product	Company	Website	Country	Technology	Materials	Resolution	Speed
Life-Printer 'X'	Bio 3D Technologies	http://bio-3d.com	Singapore	Extrusion, nano-jetting	Biomaterials	10 μm	1–400 mm s^{-1}
BioScaffolder 2.1	GeSiM	http://gesim.de	Germany	Pressuredriven 3D printing; piezo-electric nanolitre pipetting; pneumatic extruders and piezodispensers	Hydrogels, biopolymers (e.g., collagen and alginate), bone cement paste, biocompatible silicones and polymer pastes	Step width: 2 μm in <i>X/Y</i> , 10 μm in <i>Z</i>	Up to 500 mm s^{-1}
TE subseries of nScrypt's Table-top series	nScrypt	http://nscrypt.com	USA	Extrusion printing	A few centipoise to 1 million centipoise; thermal plastic biopolymer materials, gels and pastes in terms of form for the materials	<i>X/Y</i> accuracy: 12 μm ; <i>Z</i> accuracy: 6 μm	<i>X/Y</i> max speed: 100 mm s^{-1} ; <i>Z</i> max speed: 50 mm s^{-1}
CellJet Cell Printer	DigiLab	http://digilabglobal.com	Japan	—	Ordinary cell media with watery consistency and viscous solutions such as hydrogels	<i>X, Y</i> motor resolution of the synQUAD is 1.5 μm and positional accuracy is $\pm 10 \mu\text{m}$ at 95% confidence	—
3D-Bioplotter	EnvisionTEC	http://envisiontec.com	Germany	Extrusion printing	Soft hydrogels over polymer melts up to hard ceramics and metals	Axis resolution (<i>X-Y-Z</i>): 0.001 mm; minimum strand diameter: 0.100 mm	0.1–150 mm s^{-1}
Fab@Home Model 3	Seraph Robotics	http://seraphrobotics.com	USA	Extrusion printing	Wide range of materials	Position accuracy: 100 μm	Max: 80 mm s^{-1} ; typical: 10 mm s^{-1}
BioFactory	RegenHU	http://regenhu.com	Swiss	Thermopolymer extruder, Ink-Jet head; direct dispenser	Medium with a viscosity up to 10 000 mPa s^{-1}	10 μm	Depend on the material type

Table 2. 3D bioprinting companies and products.

Company	Website	Founded year	Country	3D printer	Project/Products
Cyfuse Biomedical	http://cyfusebio.com	2010	Japan	Regenova: needle based spheroids printing	Cartilage and subchondral bone; Tubular tissue; Liver tissue;
TeVido Biodevices	http://tevidobiodevices.com	2011	US	Cellatier: droplet printing technology	Breast cancer; Bone;
Regenovo Biotechnology	http://regenovo.com	2013	China	Extrusion bioprinting	Blood vessel; Liver;
Aspect Biosystems	http://aspectbiosystems.com	2013	Canada	Microfluidic based bioprinting technology	Engineer tissues for Pharma R&D;
RegenHU	http://regenhu.com	2007	Swiss	BioFactory	Printed dermis equivalent; BioTrack®, a three-dimensional optical biopsy unit
Osteopore International	http://osteopore.com.sg	2003	Singapore	Polycaprolactone printing	Osteoplug; Osteomesh
Organovo Holdings	http://organovo.com	2007	US	NovoGen MMX bioprinter	exVive3D™ Liver Testing
Tissue Regeneration Systems	http://tissuesys.com	2008	US	TRS Scaffold printing	Bone reconstruction and regeneration (FDA approved)
Next 21	http://next21.info	2000	Japan	Scaffold printing	Custom-made artificial bone implants
3D Bioprinting Solutions	http://bioprinting.ru	2014	Russia	3Dbio	Mouse thyroid




Table 3. Summary of bioprinting technologies.

	Laser bioprinting	Droplet bioprinting	Extrusion bioprinting
Fabrication resolution (droplet size)	>20 μm	50–300 μm	200 μm
Spatial resolution	Medium-high	Low	Medium
Preparation time	Medium-high	Low	Low-medium
Fabrication speed	Medium-fast (200–1600 mm s^{-1})	Fast (1–10 000 droplet/s)	Slow (10–50 $\mu\text{m s}^{-1}$)
Throughput/Scalable production	Low-medium	High	Medium
Material viscosity	1–300 mPa s^{-1}	3.5–12 mPa s^{-1}	30–6 $\times 10^7$ mPa s^{-1}
Cell viability	>95%	>90%	>40–95%
Single cell control	High	Low	Low
Cell density	Medium	Low	Medium-high
Multiple cells and Material delivery	Medium	Low-medium	Medium
Cost	High	Low	Medium

ribbon [58, 59] (figure 1(b)). The laser bioprinting is a nozzle-less approach, which allows printing high cell densities and high viscosities of bio-inks without the conventional challenges associated with the droplet and extrusion bioprintings such as clogging and increasing the temperature of ejectors [60–62]. However, several shortcomings (e.g., high-cost of the printer and inability to print large constructs due to the limited width of the laser beam) have hindered the successful translation of this approach [2]. In addition, the laser bioprinting has a relatively low flow rate due to the requirement of fast gelation kinetics to obtain high shape fidelity for high resolution [2]. Moreover, in many cases the final tissue-engineering construct includes some of the metallic residue, which occurs during the printing process as a result of the evaporation of the metallic laser-absorbing layer [5, 52].

3.1.3. Extrusion bioprinting

The extrusion bioprinting approach is one of the most explored and affordable bioprinting systems. The method is increasingly applied in tissue biofabrication [63]. The extrusion bioprinting system is composed of a dispensing (ejector or multiple ejector) system and an automated three-axis (x - y - z) robotic stage controlled by stage controller [11, 52]. In this approach, a pneumatic or mechanical (piston or screw-based) dispenser is used to deposit the bio-ink with suspended cells on a building substrate [11, 52]

(figure 1(c)). The major advantages of the extrusion systems are the ability to print high viscosity materials with high cell densities at a relatively high speed with an acceptable cell viability post-printing [64, 65]. However, this approach provides a relatively low fabrication resolution ($\sim 200 \mu\text{m}$) [2, 52]. The system allows for a continuous filament of a viscous bio-ink rather than a droplet. Direct and more spatial control over the material flow can be achieved using the mechanical approach; however, this approach can result in a shear stress-induced cell deformation [66]. The pneumatic approach provides less deformation of the cells; however, precise control over the material flow is challenging as a result of delay of compressed gas volume in this system [2]. Furthermore, an acoustic nozzle-less bioprinting approach was designed for precise cell encapsulation in bio-fluids at picoliter scale with high viability, which could eliminate the issues associated with nozzle clogging in conventional ejector-based method [3, 43, 44]. The extrusion bioprinting approach has the potential to enable various innovative applications including the ability to preserve cells for transfusion medicine [67, 68] and investigate cells at a single-cell level for regenerative medicine and omic applications [69].

3.2. Patterning and assembly-based approaches

Patterning or assembly of cells enables constructing 3D tissue architectures. These patterning and assembly

techniques allow us to address some of the current challenges in 3D bioprinting technology by providing innovative experimental platforms based on high-throughput, rapid, and directed assembly of cells, cell encapsulating microgels, and spheroids. Patterning and assembly strategies [13, 70–75] target obstacles arising from structure and heterogeneity associated with large-scale applications. Development of macro-scale structures is particularly required for clinical applications. Recent additive advances in assembly techniques such as magnetic [21] and acoustic assembly [76] may allow generation of new designs and geometries, which can further lead to ordered and complex structures (figure 2) [77]. Advanced additive assembly technologies, such as self assembly [78], robotic assembly [21], Faraday acoustic assembly [76, 77, 79], bio-acoustic levitational assembly [80], and magnetic assembly [70, 72, 81–86] enable the user to organize, reorganize, and regenerate basic units to form the 3D tissue architecture. Its reconfigurable feature provides flexibility. Furthermore, it could lead to development of rapid and easy-to-use bioprinters and scaffold-free cell printing technologies [87].

3.2. Bioprinting materials/bio-inks

Mimicking the native tissue architecture and composition using 3D bioprinting approaches is quite challenging, because balancing the physical and chemical cues of the cell hosting biomaterials requires understanding of cell physiology and cell–extracellular matrix (ECM) interaction [2, 60]. Engineered 3D microenvironments can be achieved by utilizing natural (e.g., collagen, fibrin, hyaluronic acid (HA), hydroxyapatite, and alginate) and synthetic (e.g., PCL, polylactide (PLA), polyglycolide (PGA), poly(lactic-co-glycolic acid) (PLGA), and polyethylene glycol (PEG)) polymers (table 4) or hybrid biomaterials that merge natural and synthetic materials together [2, 15, 53, 88–96].

3.2.1. Natural materials


Chemical and physical compositions of the natural hydrogels can be tuned according to target tissue and cell types [97]. Physical properties of biopolymers such as stiffness, viscosity, and porosity play a critical role in the survival and functionality of generated constructs [2]. Most cell types can hydrolyze natural hydrogels and secrete their own cellular matrix, allowing space for cell growth and migration. Moreover, these matrices can be designed to contain tissue specific growth factors and chemokines such as transforming growth factor beta (TGF- β), epidermal growth factor, insulin-like growth factor as well as matrix metalloproteinase, which help to restore the chemical cues of the microenvironment [98, 99]. One of the limitations of natural hydrogels is the batch-to-batch variability, which may affect the validation of the engineered microenvironment as different batches may have slightly different compositions [2].

Collagen- and fibrinogen-based hydrogels are naturally-derived matrices and are widely used in tissue engineering [100, 101]. Collagen type I is the most abundant component of the native ECM and provide a favorable 3D environment for cell adhesion and proliferation [101]. Photocrosslinkable gelatin methacrylate (GelMA)-based hydrogel combines biological features permitting integrin-mediated cell adhesion and proteolytic degradation [2]. GelMA is broadly used in engineering artificial tissues due to its ease of manipulation and photocrosslinking properties [21]. Alginate is highly biocompatible natural polymer that can be easily crosslinked in calcium solutions; therefore, often used as bioink in 3D bioprinting applications [102–104].

Generation of 3D artificial tissues can also be achieved by utilizing reconstituted basement membranes from mouse tumors like Matrigel™ and Cultrex® into bioprinting process [105]. Basement membranes are composed of ECM containing proteins like fibronectin, laminin, and collagen IV that play important roles in cell adhesion and spatial organization [88]. These natural membranes can be applied in embedded and overlay culture to promote 3D cellular organizations. Introducing basement membrane in a bioprinting polymer solution has shown to sustain the geometrical architecture and enhance the cell function [106].

3.2.2. Synthetic and semi-synthetic materials

To overcome the drawbacks of biologically derived biomaterials such as batch-to-batch variability, a library of semi-synthetic and synthetic biomaterials have been engineered. These matrices offer a relevant alternative as they have native ECM components together with tunable material properties, resulting in better reproducibility and comparability between different studies. Thus, biocompatible synthetic polymers such as PCL, PEG, PLA, PGA, and PLGA, are frequently used in bioprinting applications [107–111]. PEG hydrogels are one of the most popular synthetic matrices used in tissue engineering [112]. PEG based hydrogels can be prepared by chemical or UV light crosslinking of the functionalized polymers with reactive chain ends, allowing cell encapsulation with high viability [72]. Biomimetic PEG hydrogels can be synthesized via the incorporation of a variety of ligands from oligopeptides to whole protein growth factors to restore matrix-derived biochemical signaling. For example, the inclusion of arginine–glycine–aspartic acid (RGD) peptides enables integrin-mediated cell adhesion and promotes migration. However, synthetic matrices are not as biologically relevant as naturally derived 3D matrices, and do not contain the signaling molecules (e.g., peptides) provided by native ECM [113]. Self-assembled peptide hydrogels are also widely used to generate 3D microenvironments for cell culture. Peptide scaffolds are made of peptide sequences that allow the scaffold to self-assemble



under certain physiological conditions, permitting cell encapsulation in the hydrogel [88]. For instance, BDTM PuraMatrixTM is a hybrid peptide hydrogel [114]. The composition of BDTM PuraMatrixTM is similar to other semi-synthetic hydrogels as it contains 99% water and only 1% amino acids. Such engineered matrix allows the control over the composition of growth factors, cytokines, ECM proteins, and hormones.

One of the most recent approaches to engineer a native-like 3D microenvironment is to use cells that can generate the natural ECM [115]. This strategy is

based on initial seeding of the porous graft with death programmed sacrificial cells that can secrete ECM and be induced to apoptosis. The devitalized graft can be further stored as an off-the-shelf product until seeded with autologous cells [115].

Bioprinting materials/bio-inks can also be designed to fulfill the mechanical and biological aspects of target tissues [116, 117]. In this regard, the selection and design of bio-ink requires critical evaluation of the physiology of native organ. For example, in load bearing organs, such as bone [118], the

Table 4. Synthetic and natural materials used in biofabrication.

Material	Type	Gelation method	Cytocompatibility	Cell type
Agarose	Natural	Thermal/chemical	<95%	HUVEC, 10T1/2
Alginate	Natural	Thermal	<95%	HeLa, RatSMC, NIH 3T3 fibroblast
Collagen	Natural	Thermal	95–75%	RFMF
Fibrin	Natural	Enzymatic	85–70%	HMVEC
Gelatin	Natural	Thermal/chemical	75–95%	Hepatocyte
Matrigel	Natural	Thermal	High, <95%	HUVEC, 10T1/2
PEG	Synthetic	Thermal/photo	High, <95%	NIH 3T3 fibroblast
PHEMA	Synthetic	Thermal/photo	Not studied	HepG2/C3A
PCL	Synthetic	Thermal	<95%	hMSC, L929 fibroblast
PLGA	Synthetic	Thermal	<95%	hMSC, L929 fibroblast

bioprinted graft should be stable enough to provide mechanical strength especially for bone tissue culturing. PCL has shown to be a good candidate as bio-ink in orthopedic applications [2, 116, 119, 120]. Composite of PCL with osteoinductive hydroxyapatite particles improves the osteogenic features of the constructs and brings them closer to the native stiffness of target tissues [121]. Hydroxyapatite particle based bio-inks can also be sequentially bioprinted with cell-loaded alginate to form complex 3D osteogenic structures [122]. Thus, the potential use of bioprinted biocompatible synthetic polymers such as PCL and PCL matrix reinforced with hydroxyapatite can enhance the mechanical and biological performance of 3D scaffolds for biomedical applications [116, 117].

4. Biomedical applications

4.1. Bioprinting for tissue regeneration and regenerative medicine

Different bioprinting approaches showed potential of additive manufacturing in which generated tissues hold promise to create tissue constructs mimicking many tissues and organs such as liver, kidney, heart, skin, neuron, and vascular systems. In this section, we highlight major approaches for generating 3D printed tissue constructs while maintaining cellular functions.


4.1.1. Vascular grafts

Tissue engineering is currently limited by vascularization challenge, which creates issues in nutrient perfusion, oxygen diffusion, and mass transportation for *in vivo* systems. Vascular grafts are well-studied models of 3D bioprinting technologies since they are directly integrated with the solution of vascularization problem. A ‘scaffold-free’ bioprinting approach was utilized for fabrication of vascular grafts (figure 3) [40, 123]. Tubular constructs were generated using cell spheroids and agarose templates (figures 3(a) and 4(b)). Multicellular spheroids were used as building blocks, and spheroids were assembled into tubular structures by using agarose templates (figure 3(c)). Additionally, vascular grafts were printed by using three different cell types: human aortic smooth muscle

cells, human aortic endothelial cells, and human dermal fibroblasts [124]. At the post-printing stage, cells are allowed to fuse [124, 125] as shown in figure 3(d), and vascular constructs were moved into a bioreactor for a maturation step designed to improve physical and mechanical properties of vascular grafts. In another approach, formation of vascular channels was achieved by combining 3D bioprinting technology with perfusion techniques (figure 4) [126]. In this study, the collagen hydrogel precursor was used for bioprinting of human umbilical vein endothelial cells (HUVECs) while vascular grafts were formed using gelatin (figure 4(a) and (b)). The printed constructs were then integrated into a polycarbonate flow chamber to form fluidic vascular grafts. Further, viability assays (figure 4(c)) confirmed that the viability of printed vascular grafts was higher under dynamic flow conditions.

4.1.2. Skin

Bioprinting of a skin tissue is one of the most promising examples of bioprinting for several applications, such as development of topical drugs, wound healing studies, and dermal toxicology research. Various approaches have been developed to engineer cellular microenvironment and physiology of human skin. For instance, to develop skin substitutes, fibroblasts and keratinocytes were printed on a stabilizing matrix (Matriderm) via laser assisted bioprinting technique [127]. Both *in vitro* and *in vivo* trials showed that neovascularization could be achieved by employing this technique. In another study, a direct-forward bioprinting technique was used to print amniotic fluid-derived stem cells (AFSCs) for wound healing and skin regeneration in a mouse model [128] (figure 5). This technique used a mixture of AFSCs and bone marrow-derived mesenchymal stem cells (MSCs) that were suspended in fibrin–collagen matrix. At week 2, formation of a well-defined and ordered epidermal layer was observed for MSC and AFSC treated wounds (figures 5(b) and (c)), while epidermal layer formation was poor for the wounds treated with gel only (figure 5(a)). However, based on fluorescence labeling results (figures 5(d) and (e)) cell migration did not occur for MSC and AFSC printed samples, which




suggested that printed cells did not penetrate into regenerating tissue.

4.1.3. Neuron

3D bioprinting of neural cells to construct brain-like or neuronal structures is highly desirable to model neuronal pathogenesis, regeneration, and networks, as well as provide a platform to investigate new therapeutic treatments (e.g., Alzheimer and Parkinson's drugs) [41, 129]. However, one of the main challenges of this approach is the difficulty to recapitulate the brain multi-layers, specifically in the medial or sagittal plane (figure 6(a)) [129, 130]. In addition, patterning neuronal tissues that are functional post-printing remains a challenge. Recently, an extrusion 3D bioprinter was used to create distinct layers of primary neural cells encapsulated in a natural hydrogel [130] (figure 6(b)). In this study, the authors built a 3D structure with multilayered architecture that mimics brain cortical tissue. The hydrogel used in this study was based on a natural RGD peptide-modified gellan gum. Confocal microscopy demonstrated that printed cells formed 3D neural networks after 5 days in culture (figures 6(c) and (d)). In addition, cell viability results demonstrated that there was no significant difference between the printed group compared to the control

(non-printed) group for up to 5 days post-printing (figures 6(e) and (f)). In another study, a piezoelectric droplet bioprinter was used to pattern two adult rat central nervous system cells [131] (i.e., retinal ganglion cell (RGC) neurons and retinal glia cells). No significant differences in cell viability and neurite outgrowth were observed between the printed and non-printed control cells. However, when glia cells were used as a substrate for printed and control cells, the RGC neurite outgrowth was increased significantly. Recently, a novel bioacoustic levitation assembly (BAL) approach was developed to engineer 3D brain-like constructs [80] (figure 6). Random suspended human neural progenitor cells (hNPCs) were levitated to the nearest nodes of acoustic standing waves in a fibrinogen solution by acoustic radiation force and assembled into a multilayered cell construct (figure 6(g)). The interlayer spacing can be flexibly tuned by acoustic frequency in tens of seconds. The levitated hNPCs were immobilized in the fibrin hydrogel construct via gelation and differentiated into neural cells in the 3D microenvironment to form both inter- and intra-layer neural connections (figure 6(h)). BAL provides a simple, rapid, and biocompatible method to bioengineer multilayer tissue constructs for



a wide array of applications including neuroscience, cardiovascular, and cancer biology.

4.1.4. Bone


The studies in bone regeneration often encounter two major problems: graft porosity and vascularization [132–136]. Gene therapy represents an ideal approach for bone regeneration while delivering regenerative molecules to the specific tissues [137]. A new technique has been developed [138], which integrates effective printing strategies with gene therapy for bone regeneration studies. As an addition to bioprinting technique, plasmid DNA encoding bone morphogenetic protein-2 (BMP-2) is added to the constructs to induce osteogenic differentiation. The performance of porous constructs was better than the non-porous ones in means of BMP-2 production. Porosity and high BMP-2 production enhanced the rate of osteogenic differentiation. Expression of osteogenic markers, alkaline phosphatase, and osteocalcin were higher for porous and BMP-2 induced constructs suggesting that porosity combined with gene induction provided a suitable microenvironment for bone regeneration. Recently, another approach has been reported, which incorporates bioprinting technology with a nanoliter gel droplet system to create biomimetic fibrocartilage microenvironment [37]. Human

MSCs were encapsulated in bio-ink, which is gelatin-based metacrylated hydrogel. In addition, BMP-2 and transforming growth factor $\beta 1$ (TGF- $\beta 1$) were added to mimic the native fibrocartilage phase of the bone. Quantitative RT-PCR analysis supported that upregulation of osteogenesis and chondrogenesis occurred in 3D fibrocartilage model, thus making this approach as a functional tissue model system.

4.1.5. Liver

Primary hepatocytes and stem cell derived hepatocytes are heavily used for the tissue engineering of liver tissues [29, 139–146]. However hepatocytes lose their functionality easily under culture conditions [29]. To sustain long-term hepatocyte functionality, a new technique has been reported [147], which utilizes bioprinting technology to form hepatic cord like tissues called ‘canaliculi’. Rat hepatocytes were cultured and canaliculi formation was observed starting from day 3 with collagen matrix. Expression of the apical marker MRP2 and basolateral marker CD147 verified the functionality of hepatocytes.

A biomimetic ECM system has been used for evaluation of hepatocyte function on different ECM-based hydrogels [148]. Primary human hepatocytes were cultured in liver ECM extracts, which was combined with Collagen Type I, HA or



heparin-conjugated HA (HP). Primary human hepatocytes were maintained in sandwich-like hydrogels for 4 weeks. Increased hepatocyte metabolism, steady levels of secreted albumin, and urea confirmed that customized ECM-based hydrogels might be a suitable cell expansion platform for cell therapy, toxicology experiments, and further drug screening studies.

Another approach has been recently reported [149] for the biofabrication of *in vitro* 3D liver model. Multi-layered tissue constructs were formed by stacking rat and human hepatocyte cells with endothelial cell layers. This work showed that multilayered cellular architecture could be successfully used as a liver analogue for drug studies and other biomedical applications. In addition, a recent scaffold-free acoustic node assembly method was developed to bioengineer 3D *in vitro* tissue model. Thousands of tissue spheroids in a fluidic environment can be rapidly assembled into a predefined architecture in seconds. The assembled architecture can be dynamically reconfigured to diverse patterns by altering the wave frequency. Assembly of hepatocyte spheroids was demonstrated for generation of 3D liver model. Formation of bile canaliculi and hepatocyte gap junctions was observed in the bioengineered liver model via anti-MRP2 and anti-Connexin 32 immunostaining after 6 days in culture. This acoustic node spheroid


assembly strategy represents an efficient and rapid way to generate 3D tissue models with a control over the predetermined geometric patterns. It also allows switching between patterns in a matter of seconds using high throughput assembly of spheroids guided by vibrations.

4.2. Bioprinting for various biomedical applications

Recent advances in cell manipulation and bioprinting technologies have allowed for various biomedical applications, including cryoprinting of cells for biobanking [67] and generation of 3D models for drug screening [40, 123–129].

4.2.1. Drug discovery

Development of *in vitro* tissue models holds a great promise for drug discovery studies [143]. Drug discovery is likely to be one of the most promising and growing area in medical applications of 3D bioprinting while technologies for artificial organs may incur delays due to regulatory hurdles. Recent technological advancements have accelerated drug design and discovery significantly, but the number of approved experimental platforms is still insufficient due to employment of 2D monolayer systems. Miniaturized 3D tissue models are valuable experimental platforms for design, discovery, and development of new generation drugs, since they mimic native microenvironment



of the tissues more accurately than 2D cell cultures [83, 150–154]. 3D tissue models have a high potential to evaluate and predict success or failure of drug candidates in preclinical stages [155, 156]. These microsystems offer more predictive and cost-effective alternatives to *in vitro* or animal-based preclinical drug screening [155]. The applications of 3D printing in drug discovery can provide many other benefits such as customization and personalization of medical products and drugs, fast and precise drug response, and increased output of drug discovery while decreasing preclinical trial costs.

Many drug screening studies have been performed by using different bioprinting platforms such as cell spheroids [157–160], cell encapsulation [161, 162], and microfluidic systems [163, 164]. Recently, an array type drug screening platform was used as a droplet bioprinting technology to produce sub-nanoliter droplets [165]. It describes the microfabrication of CYP3A4 based protein array for multiplexing studies. In another approach, a valve-based bioprinter was utilized to fabricate a 3D lung model for drug evaluation [166]. The 3D architecture was generated by layer-by-layer approach for high-throughput drug screening.

Employment of 3D tissue constructs could provide better results in drug development and evaluation due to their ability to mimic cellular structures, while reducing the number of animals utilized for drug development studies [152].

4.2.1. Biopreservation

Conventional cryopreservation methods use bulk volumes that impede proper cooling and rewarming, causing detrimental alteration of cells during biopreservation [167–172]. Utilizing bioprinting technology to transform a bulk sample of cells into micro- and nano-liter droplets can address the challenges associated with conventional cryopreservation (e.g., ice crystal formation) [167]. Recently, a bioprinting approach in conjunction with innovative bio-inspired cryo-inks was utilized to vitrify red blood cells (RBCs) [67]. The bioprinter generates considerably smaller volumes of cell-encapsulated droplets (<0.15 nl), with the aim of reducing the unfavorable effects on RBCs by eliminating the need for high cryoprotectant concentrations to achieve vitrification, and it provides ultra-high cooling and rewarming rates that enable preserving cells minimizing ice crystal formation. The cells were also loaded with a bio-inspired ectoine-based cryo-ink, which acts as a non-toxic cryoprotectant, to eliminate the toxic effect associated with conventional cryoprotectants (e.g., dimethyl sulfoxide and glycerol) [167, 173]. Following rewarming, the biopreserved cells maintained their unique morphology, mechanics, and function. The bio-inspired bioprinting approach has the potential to create new avenues to biopreserve cells (e.g., stem cells, lymphocytes, and oocytes) for regenerative and reproductive medicine applications [7, 68, 174].

5. Future perspective and challenges

In this review, we have illustrated current guiding principles for 3D bioprinting in tissue fabrication, as well as recent advances and technological developments. The speed at which our knowledge has advanced with additive manufacturing and automated printing systems shows a promise to expand our basic science and engineering capabilities towards addressing healthcare problems.

One of the major milestones in 3D bioprinting is to fabricate and mimic cellular microenvironments from molecular to macroscopic scales in an autonomously ordered manner for tissue engineering and regenerative medicine. Recently developed 3D bioprinting technologies provide multiple approaches for biofabrication of tissue constructs. In particular, innovative technologies that engineer 3D cell microenvironment hold promise to facilitate the artificial tissue fabrication, and eventually to enhance our understanding from cellular interactions to tissue

formation. By cooperation of various cutting-edge technologies, such as microfluidic systems [147, 149], biopatterning [37], and layer-by-layer assembly [149, 175] biomanufacturing of micro-tissue constructs within scaffolds or scaffold-free environments has been achieved. Despite the great progress of bio-material development for tissue engineering, there are still certain challenges that need to be overcome. For instance, vascularization is one of the most important limiting parameters in tissue engineering and bioprinting [176, 177]. Due to restricted structure and vascularization challenges, hypoxia, apoptosis, and immediate cell death occurs, and thus, there is an urgent need to developed innovative solutions for vascular networks. Up to now, meeting this challenge has been mostly attempted by fabricating porous scaffolds [178], which provides sufficient space for vascularization. However, this approach cannot overcome the vascularization challenge completely due to the diffusion of cells and other materials into these porous structures [179]. Evidently, advances in bioprinting technologies will provide potential solutions to overcome this problem while forming interconnected, well-defined vascular structures during biomanufacturing process. On the other hand, mechanical strength and stability in 3D tissue engineering are among the key requirements [180]. For instance, in regeneration of hard (e.g., bone) and soft (e.g., vascular grafts) tissues, elastic modulus is an important parameter that needs to be optimized in those tissue constructs [181–183]. Furthermore, the development of a fully closed bioprinting system that integrates printing and post-printing processes such as *in vitro* culture and maturation of tissue constructs is still a challenge. Once the challenges mentioned above are addressed, scaling up bioprinting technologies will potentially improve rapid clinical solutions and advance medical implants. Further, we envision that the integration of cells and biomaterials through bioprinting with microfluidic technologies are likely to create unique microenvironments for various applications in cancer biology, tissue engineering, and regenerative medicine [172, 184–188]. Additionally, developments on high-throughput biomanufacturing of 3D architectures will pave the way for further advancements of *in vitro* screening and diagnostic applications, potentially enabling complex organ constructs.

Acknowledgments

We thank Jedediah Lewis, a doctoral student in Stanford University's Biosciences Program and BAMB Labs at Stanford as well as Alyssa Holman and Srikar Srivatsa, interns at the Canary Center at Stanford for their feedback on the manuscript. We would also like to thank Dr Mark Lifson for his

feedback on the manuscript. This work was supported by NSF CAREER 1150733, NIH R15HL115556, NIH R21HL112114, and NIH R01EB015776. Currently, A Arslan-Yildiz and S Guven are at the Department of Bioengineering, Izmir Institute of Technology and the Izmir Biomedicine and Genome Center, Dokuz Eylul University, Izmir, Turkey, respectively. We also would like to acknowledge the UNESCO-Loreal International Fellowship for their support.

References

- [1] Zhao S, Cong H and Pan T 2009 Direct projection on dry-film photoresist (DP 2): do-it-yourself three-dimensional polymer microfluidics *Lab Chip* **9** 1128–32
- [2] Malda J et al 2013 25th anniversary article: engineering hydrogels for biofabrication *Adv. Mater.* **25** 5011–28
- [3] Tasoglu S and Demirci U 2013 Bioprinting for stem cell research *Trends Biotechnol.* **31** 10–9
- [4] Derby B 2012 Printing and prototyping of tissues and scaffolds *Science* **338** 921–6
- [5] Guillotin B and Guillemot F 2011 Cell patterning technologies for organotypic tissue fabrication *Trends Biotechnol.* **29** 183–90
- [6] Zhang Y, Yu Y, Akkouch A, Dababneh A, Dolati F and Ozbolat I T 2015 *In vitro* study of directly bioprinted perfusable vasculature conduits *Biomater. Sci.* **3** 134–43
- [7] El Assal R, Chen P and Demirci U 2015 Highlights from the latest articles in advanced biomanufacturing at micro- and nano-scale *Nanomedicine* **10** 347
- [8] Tasoglu S, Gurkan U A, Wang S and Demirci U 2013 Manipulating biological agents and cells in micro-scale volumes for applications in medicine *Chem. Soc. Rev.* **42** 5788–808
- [9] Marga F et al 2012 Toward engineering functional organ modules by additive manufacturing *Biofabrication* **4** 022001
- [10] Yu Y and Ozbolat I T 2014 Tissue strands as 'bioink' for scale-up organ printing *2014 36th Annual Int. Conf. of the IEEE Engineering in Medicine and Biology Society* pp 1428–31
- [11] Seol Y-J, Kang H-W, Lee S J, Atala A and Yoo J J 2014 Bioprinting technology and its applications *Eur. J. Cardio-Thoracic Surg.* **46** 342–8
- [12] Park J Y et al 2014 A comparative study on collagen type I and hyaluronic acid dependent cell behavior for osteochondral tissue bioprinting *Biofabrication* **6** 035004
- [13] Sasai Y 2013 Cytosystems dynamics in self-organization of tissue architecture *Nature* **493** 318–26
- [14] Durdu S et al 2014 Luminal signalling links cell communication to tissue architecture during organogenesis *Nature* **515** 120–4
- [15] Guven S, Chen P, Inci F, Tasoglu S, Erkmen B and Demirci U 2015 Multiscale assembly for tissue engineering and regenerative medicine *Trends Biotechnol.* (doi:10.1016/j.tibtech.2015.02.003)
- [16] Ventola C L 2014 Medical applications for 3D printing: current and projected uses *Pharmacy Therapeutics* **39** 704
- [17] Villar G, Graham A D and Bayley H 2013 A tissue-like printed material *Science* **340** 48–52
- [18] Munch E, Launey M E, Alsem D H, Saiz E, Tomsia A P and Ritchie R O 2008 Tough, bio-inspired hybrid materials *Science* **322** 1516–20
- [19] Murphy W L and Mooney D J 2002 Molecular-scale biomimicry *Nat. Biotechnol.* **20** 30–1
- [20] Kouwer P H J et al 2013 Responsive biomimetic networks from polyisocyanopeptide hydrogels *Nature* **493** 651–5
- [21] Tasoglu S, Diller E, Guven S, Sitti M and Demirci U 2014 Untethered micro-robotic coding of three-dimensional material composition *Nat. Commun.* **5** 3124
- [22] Ma P X 2008 Biomimetic materials for tissue engineering *Adv. Drug Deliv. Rev.* **60** 184–98
- [23] Hoch E, Tovar G E and Borchers K 2014 Bioprinting of artificial blood vessels: current approaches towards a demanding goal *Eur. J. Cardio-Thoracic Surg.* **46** 767–78
- [24] Daly R, Harrington T S, Martin G D and Hutchings I M 2015 Inkjet printing for pharmaceuticals—a review of research and manufacturing *Int. J. Pharmaceutics* **494** 554–67
- [25] Kannan S 2014 The 3D bioprinting revolution *Harv. Sci. Rev.*
- [26] Williams J M et al 2005 Bone tissue engineering using polycaprolactone scaffolds fabricated via selective laser sintering *Biomaterials* **26** 4817–27
- [27] Vaidya M 2015 Startups tout commercially 3D-printed tissue for drug screening *Nat. Med.* **21** 2–2
- [28] Hardwick R et al 2015 Functional characterization of three-dimensional (3D) human liver tissues generated by an automated bioprinting platform *Experimental Biology Conf.*
- [29] Bale S S et al 2014 *In vitro* platforms for evaluating liver toxicity *Exp. Biol. Med.* **239** 1180–91
- [30] Ali M, Pages E, Ducom A, Fontaine A and Guillemot F 2014 Controlling laser-induced jet formation for bioprinting mesenchymal stem cells with high viability and high resolution *Biofabrication* **6** 045001
- [31] Kingsley D, Dias A, Chrisey D and Corr D 2013 Single-step laser-based fabrication and patterning of cell-encapsulated alginate microbeads *Biofabrication* **5** 045006
- [32] Guillemot F et al 2010 High-throughput laser printing of cells and biomaterials for tissue engineering *Acta Biomaterialia* **6** 2494–500
- [33] Cui X, Boland T, D'Lima D D and Lotz M K 2012 Thermal inkjet printing in tissue engineering and regenerative medicine *Recent Patents Drug Deliv. Formulation* **6** 149
- [34] Xu T, Zhao W, Zhu J-M, Albanna M Z, Yoo J J and Atala A 2013 Complex heterogeneous tissue constructs containing multiple cell types prepared by inkjet printing technology *Biomaterials* **34** 130–9
- [35] Arai K, Iwanaga S, Toda H, Genci C, Nishiyama Y and Nakamura M 2011 Three-dimensional inkjet biofabrication based on designed images *Biofabrication* **3** 034113
- [36] Cui X, Gao G, Yonezawa T and Dai G 2014 Human cartilage tissue fabrication using three-dimensional inkjet printing technology *JoVE* **88** e51294
- [37] Gurkan U A et al 2014 Engineering anisotropic biomimetic fibrocartilage microenvironment by bioprinting mesenchymal stem cells in nanoliter gel droplets *Mol. Pharmaceutics* **11** 2151–9
- [38] Ceyhan E et al 2012 Prediction and control of number of cells in microdroplets by stochastic modeling *Lab Chip* **12** 4884–93
- [39] Iwami K, Noda T, Ishida K, Morishima K, Nakamura M and Umeda N 2010 Bio rapid prototyping by extruding/aspirating/refilling thermoreversible hydrogel *Biofabrication* **2** 014108
- [40] Norotte C, Marga F S, Niklason L E and Forgacs G 2009 Scaffold-free vascular tissue engineering using bioprinting *Biomaterials* **30** 5910–7
- [41] Owens C M, Marga F, Forgacs G and Heesch C M 2013 Biofabrication and testing of a fully cellular nerve graft *Biofabrication* **5** 045007
- [42] Obregon F, Vaquette C, Ivanovski S, Huttmacher D and Bertassoni L 2015 Three-dimensional bioprinting for regenerative dentistry and craniofacial tissue engineering *J. Dental Res.* **94** 0022034515588885
- [43] Demirci U 2006 Acoustic picoliter droplets for emerging applications in semiconductor industry and biotechnology *J. Microelectromech. Syst.* **15** 957–66
- [44] Demirci U and Montesano G 2007 Single cell epitaxy by acoustic picolitre droplets *Lab Chip* **7** 1139–45
- [45] Durmus N G, Tasoglu S and Demirci U 2013 Bioprinting: functional droplet coding of networks *Nat. Mater.* **12** 478–9
- [46] Tasoglu S, Kaynak G, Szeri A J, Demirci U and Muradoglu M 2010 Impact of a compound droplet on a flat surface: a model for single cell epitaxy *Phys. Fluids* **22** 082103

- [47] Moon S, Ceyhan E, Gurkan U A, Demirci U and Borlongan C V 2011 Statistical modeling of single target cell encapsulation *PLoS One* **6** e21580
- [48] Cui X and Boland T 2009 Human microvasculature fabrication using thermal inkjet printing technology *Biomaterials* **30** 6221–7
- [49] Cui X, Dean D, Ruggeri Z M and Boland T 2010 Cell damage evaluation of thermal inkjet printed Chinese hamster ovary cells *Biotechnol. Bioeng.* **106** 963–9
- [50] Xu F, Sridharan B, Wang S, Gurkan U A, Syverud B and Demirci U 2011 Embryonic stem cell bioprinting for uniform and controlled size embryoid body formation *Biomicrofluidics* **5** 022207
- [51] Moon S et al 2009 Layer by layer three-dimensional tissue epitaxy by cell-laden hydrogel droplets *Tissue Eng. C* **16** 157–66
- [52] Ferris C J, Gilmore K G and Wallace G G 2013 Biofabrication: an overview of the approaches used for printing of living cells *Appl. Microbiol. Biotechnol.* **97** 4243–58
- [53] Skardal A and Atala A 2014 Biomaterials for integration with 3D bioprinting *Ann. Biomed. Eng.* **43** 730–46
- [54] Kim J D, Choi J S, Kim B S, Chan Choi Y and Cho Y W 2010 Piezoelectric inkjet printing of polymers: stem cell patterning on polymer substrates *Polymer* **51** 2147–54
- [55] Xu T, Baicu C, Aho M, Zile M and Boland T 2009 Fabrication and characterization of bio-engineered cardiac pseudo tissues *Biofabrication* **1** 035001
- [56] Odde D J and Renn M J 1999 Laser-guided direct writing for applications in biotechnology *Trends Biotechnol.* **17** 385–9
- [57] Nahmias Y and Odde D J 2006 Micropatterning of living cells by laser-guided direct writing: application to fabrication of hepatic–endothelial sinusoid-like structures *Nat. Protocols* **1** 2288–96
- [58] Koch L, Gruene M, Unger C and Chichkov B 2013 Laser assisted cell printing *Curr. Pharmaceutical Biotechnol.* **14** 91–7
- [59] Guillemot F, Souquet A, Catros S and Guillotin B 2010 Laser-assisted cell printing: principle, physical parameters versus cell fate and perspectives in tissue engineering *Nanomedicine* **5** 507–15
- [60] Hribar K C, Soman P, Warner J, Chung P and Chen S 2014 Light-assisted direct-write of 3D functional biomaterials *Lab Chip* **14** 268–75
- [61] Gruene M et al 2010 Laser printing of stem cells for biofabrication of scaffold-free autologous grafts *Tissue Eng. C* **17** 79–87
- [62] Koch L et al 2009 Laser printing of skin cells and human stem cells *Tissue Eng. C* **16** 847–54
- [63] Jones N 2012 Science in three dimensions: the print revolution *Nature* **487** 22–3
- [64] Cohen D L, Lipton J I, Bonassar L J and Lipson H 2010 Additive manufacturing for *in situ* repair of osteochondral defects *Biofabrication* **2** 035004
- [65] Duan B, Hockaday L A, Kang K H and Butcher J T 2013 3D bioprinting of heterogeneous aortic valve conduits with alginate/gelatin hydrogels *J. Biomed. Mater. Res. A* **101** 1255–64
- [66] Ozbolat I T and Yu Y 2013 Bioprinting toward organ fabrication: challenges and future trends *IEEE Trans. Biomed. Eng.* **60** 691–9
- [67] El Assal R et al 2014 Bio-inspired cryo-ink preserves red blood cell phenotype and function during nanoliter vitrification *Adv. Mater.* **26** 5815–22
- [68] Zhang X et al 2012 Nanoliter droplet vitrification for oocyte cryopreservation *Nanomedicine* **7** 553–64
- [69] Moon S et al 2011 Drop-on-demand single cell isolation and total RNA analysis *PLoS One* **6** e17455
- [70] Xu F et al 2011 Three-dimensional magnetic assembly of microscale hydrogels *Adv. Mater.* **23** 4254–60
- [71] Demirörs A F, Pillai P P, Kowalczyk B and Grzybowski B A 2013 Colloidal assembly directed by virtual magnetic moulds *Nature* **503** 99–103
- [72] Tasoglu S et al 2013 Paramagnetic levitational assembly of hydrogels *Adv. Mater.* **25** 1137–43
- [73] Kalsin A M, Fialkowski M, Paszewski M, Smoukov S K, Bishop K J and Grzybowski B A 2006 Electrostatic self-assembly of binary nanoparticle crystals with a diamond-like lattice *Science* **312** 420–4
- [74] Martins A, Alves da Silva M L, Faria S, Marques A P, Reis R L and Neves N M 2011 The influence of patterned nanofiber meshes on human mesenchymal stem cell osteogenesis *Macromol. Biosci.* **11** 978–87
- [75] Melchels F P, Feijen J and Grijpma D W 2010 A review on stereolithography and its applications in biomedical engineering *Biomaterials* **31** 6121–30
- [76] Chen P et al 2014 Microscale assembly directed by liquid-based template *Adv. Mater.* **26** 5936–41
- [77] Xu F et al 2011 The assembly of cell-encapsulating microscale hydrogels using acoustic waves *Biomaterials* **32** 7847–55
- [78] Rezende R A et al 2012 Design, physical prototyping and initial characterisation of ‘lockyballs’ this paper reports the fabrication of interlockable microscale scaffolds using two photon polymerization (2PP) and proposes a ‘lockyball’ approach for tissue self-assembly for biofabrication *Virtual Phys. Prototyping* **7** 287–301
- [79] Chen P, Güven S, Usta O B, Yarmush M L and Demirci U 2015 Biotunable acoustic node assembly of organoids *Adv. Healthc. Mater.* **4** 1937–43
- [80] Bouyer C, Chen P, Guven S, Demirtas T, Nieland T, Padilla F and Demirci U 2015 A bio-acoustic levitational (BAL) assembly method for engineering of multilayered, three-dimensional brain-like constructs, using human embryonic stem cells derived neuro-progenitors *Adv. Mater.* (doi:10.1002/adma.201503916)
- [81] Tasoglu S, Yu C, Gungordu H, Guven S, Vural T and Demirci U 2014 Guided and magnetic self-assembly of tunable magnetoceptive gels *Nat. Commun.* **5** 4702
- [82] Tasoglu S, Yu C H, Liaudanskaya V, Guven S, Migliaresi C and Demirci U 2015 Magnetic levitational assembly for living material fabrication *Adv. Healthc. Mater.* **4** 1420–1420
- [83] Xu F, Beyazoglu T, Hefner E, Gurkan U A and Demirci U 2011 Automated and adaptable quantification of cellular alignment from microscopic images for tissue engineering applications *Tissue Eng. C* **17** 641–9
- [84] Xu F et al 2012 Release of magnetic nanoparticles from cell-encapsulating biodegradable nanobiomaterials *ACS Nano* **6** 6640–9
- [85] Durmus N G et al 2015 Magnetic levitation of single cells *Proc. Natl Acad. Sci.* **112** E3661–8
- [86] Tasoglu S et al 2015 Levitational image cytometry with temporal resolution *Adv. Mater.* **27** 3901–8
- [87] Xu F et al 2011 Living bacterial sacrificial porogens to engineer decellularized porous scaffolds *PLoS One* **6** e19344
- [88] Enam S and Jin S 2015 Substrates for clinical applicability of stem cells *World J. Stem Cells* **7** 243
- [89] Pearce M E, Melanko J B and Salem A K 2007 Multifunctional nanorods for biomedical applications *Pharmaceutical Res.* **24** 2335–52
- [90] Foss C, Merzari E, Migliaresi C and Motta A 2012 Silk fibroin/hyaluronic acid 3D matrices for cartilage tissue engineering *Biomacromolecules* **14** 38–47
- [91] Ural E, Kesenci K, Fambri L, Migliaresi C and Piskin E 2000 Poly (D, L-lactide/ε-caprolactone)/hydroxyapatite composites *Biomaterials* **21** 2147–54
- [92] Malafaya P B, Silva G A and Reis R L 2007 Natural–origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications *Adv. Drug Deliv. Rev.* **59** 207–33
- [93] Applegate M B et al 2015 Laser-based three-dimensional multiscale micropatterning of biocompatible hydrogels for customized tissue engineering scaffolds *Proc. Natl Acad. Sci.* **2015** 09405
- [94] Sayin E, Baran E T and Hasirci V 2014 Protein-based materials in load-bearing tissue-engineering applications *Regenerative Med.* **9** 687–701

- [95] Singh A and Peppas N A 2014 Hydrogels and scaffolds for immunomodulation *Adv. Mater.* **26** 6530–41
- [96] Teuschl A H, van Griensven M and Redl H 2014 Sericin removal from raw *Bombyx mori* silk scaffolds of high hierarchical order *Tissue Eng. C* **20** 431–9
- [97] Gurkan U A, Tasoglu S, Kavaz D, Demirel M C and Demirci U 2012 Emerging technologies for assembly of microscale hydrogels *Adv. Healthc. Mater.* **1** 149–58
- [98] Guvendiren M and Burdick J A 2013 Engineering synthetic hydrogel microenvironments to instruct stem cells *Curr. Opin. Biotechnol.* **24** 841–6
- [99] Nguyen M K and Alsberg E 2014 Bioactive factor delivery strategies from engineered polymer hydrogels for therapeutic medicine *Prog. Polym. Sci.* **39** 1235–65
- [100] Hunt N C and Grover L M 2010 Cell encapsulation using biopolymer gels for regenerative medicine *Biotechnol. Lett.* **32** 733–42
- [101] Walters B and Stegemann J 2014 Strategies for directing the structure and function of three-dimensional collagen biomaterials across length scales *Acta Biomaterialia* **10** 1488–501
- [102] Pataky K, Braschler T, Negro A, Renaud P, Lutolf M P and Brugger J 2012 Microdrop printing of hydrogel bioinks into 3D tissue-like geometries *Adv. Mater.* **24** 391–6
- [103] Bonino C A, Efimenko K, Jeong S I, Krebs M D, Alsberg E and Khan S A 2012 Three-dimensional electrospun alginate nanofiber mats via tailored charge repulsions *Small* **8** 1928–36
- [104] Jeon O and Alsberg E 2013 Photofunctionalization of alginate hydrogels to promote adhesion and proliferation of human mesenchymal stem cells *Tissue Eng. A* **19** 1424–32
- [105] Kleinman H K and Martin G R 2005 Matrigel: basement membrane matrix with biological activity *Semin. Cancer Biol.* **15** 378–86
- [106] Poldervaart M T et al 2014 Prolonged presence of VEGF promotes vascularization in 3D bioprinted scaffolds with defined architecture *J. Control. Release* **184** 58–66
- [107] Bölgen N, Vargel I, Korkusuz P, Menceloğlu Y Z and Pişkin E 2007 *In vivo* performance of antibiotic embedded electrospun PCL membranes for prevention of abdominal adhesions *J. Biomed. Mater. Res. B* **81** 530–43
- [108] Kirkpatrick C J 2014 Developing cellular systems *in vitro* to simulate regeneration *Tissue Eng. A* **20** 1355–7
- [109] Jabbari E 2011 Bioconjugation of hydrogels for tissue engineering *Curr. Opin. Biotechnol.* **22** 655–60
- [110] Peppas N, Huang Y, Torres-Lugo M, Ward J and Zhang J 2000 Physicochemical foundations and structural design of hydrogels in medicine and biology *Annu. Rev. Biomed. Eng.* **2** 9–29
- [111] Watson B M et al 2015 Biodegradable, phosphate-containing, dual-gelling macromers for cellular delivery in bone tissue engineering *Biomaterials* **67** 286–96
- [112] Yang X, Sarvestani S K, Moeinzadeh S, He X and Jabbari E 2012 Three-dimensional-engineered matrix to study cancer stem cells and tumorsphere formation: effect of matrix modulus *Tissue Engineering Part A* **19** 669–84
- [113] Kim S-H, Turnbull J and Guimond S 2011 Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor *J. End.* **209** 139–51
- [114] Leung G, Wang Y C and Wu W 2011 Peptide nanofiber scaffold for brain tissue reconstruction *Methods Enzymology* **508** 177–90
- [115] Bourguine P E, Scotti C, Pigeot S, Tchang L A, Todorov A and Martin I 2014 Osteoinductivity of engineered cartilaginous templates devitalized by inducible apoptosis *Proc. Natl Acad. Sci.* **111** 17426–31
- [116] Puppi D et al 2012 Additive manufacturing of wet-spun polymeric scaffolds for bone tissue engineering *Biomed. Microdevices* **14** 1115–27
- [117] Santis R et al 2013 Advanced composites for hard-tissue engineering based on PCL/organic–inorganic hybrid fillers: from the design of 2D substrates to 3D rapid prototyped scaffolds *Polym. Compos.* **34** 1413–7
- [118] Scotti C et al 2010 Recapitulation of endochondral bone formation using human adult mesenchymal stem cells as a paradigm for developmental engineering *Proc. Natl Acad. Sci.* **107** 7251–6
- [119] Esposito A R et al 2013 PLDLA/PCL-T scaffold for meniscus tissue engineering *BioResearch Open Access* **2** 138–47
- [120] Bartolo P, Domingos M, Gloria A and Ciurana J 2011 BioCell printing: integrated automated assembly system for tissue engineering constructs *CIRP Ann.—Manuf. Technol.* **60** 271–4
- [121] Calandrelli L et al 2004 Natural and synthetic hydroxyapatite filled PCL: mechanical properties and biocompatibility analysis *J. Bioactive Compatible Polym.* **19** 301–13
- [122] Catros S et al 2011 Laser-assisted bioprinting for creating on-demand patterns of human osteoprogenitor cells and nano-hydroxyapatite *Biofabrication* **3** 025001
- [123] Mironov V, Visconti R P, Kasyanov V, Forgacs G, Drake C J and Markwald R R 2009 Organ printing: tissue spheroids as building blocks *Biomaterials* **30** 2164–74
- [124] Marga F, Jakab K, Khatiwala J, Shephard B, Dorfman S and Forgacs G 2011 Organ printing: a novel tissue engineering paradigm *IFMBE Proc.* vol 37
- [125] Perez-Pomares J M and Foty R A 2006 Tissue fusion and cell sorting in embryonic development and disease: biomedical implications *Bioessays* **28** 809–21
- [126] Lee V K et al 2014 Creating perfused functional vascular channels using 3D bio-printing technology *Biomaterials* **35** 8092–102
- [127] Michael S, Sorg H, Peck C T, Koch L, Deiwick A, Chichkov B, Vogt P M and Reimers K 2013 Tissue engineered skin substitutes created by laser-assisted bioprinting form skin-like structures in the dorsal skin fold chamber in mice *Plos One* **8** e57741
- [128] Skardal A et al 2012 Bioprinted amniotic fluid-derived stem cells accelerate healing of large skin wounds *Stem Cells Transl. Med.* **1** 792
- [129] Lee W et al 2009 Three-dimensional bioprinting of rat embryonic neural cells *Neuroreport* **20** 798–803
- [130] Lozano R et al 2015 3D printing of layered brain-like structures using peptide modified gellan gum substrates *Biomaterials* **67** 264–73
- [131] Lorber B, Hsiao W-K, Hutchings I M and Martin K R 2014 Adult rat retinal ganglion cells and glia can be printed by piezoelectric inkjet printing *Biofabrication* **6** 015001
- [132] Cheng C W, Solorio L D and Alsberg E 2014 Decellularized tissue and cell-derived extracellular matrices as scaffolds for orthopaedic tissue engineering *Biotechnol. Adv.* **32** 462–84
- [133] Gurkan U A and Akkus O 2008 The mechanical environment of bone marrow: a review *Ann. Biomed. Eng.* **36** 1978–91
- [134] Karageorgiou V and Kaplan D 2005 Porosity of 3D biomaterial scaffolds and osteogenesis *Biomaterials* **26** 5474–91
- [135] Fedorovich N E, Haverslag R T, Dhert W J A and Alblas J 2010 The role of endothelial progenitor cells in prevascularized bone tissue engineering: development of heterogeneous constructs *Tissue Eng. A* **16** 2355–67
- [136] Lutolf M R et al 2003 Repair of bone defects using synthetic mimetics of collagenous extracellular matrices *Nat. Biotechnol.* **21** 513–8
- [137] Pensak M J and Lieberman J R 2013 Gene therapy for bone regeneration *Curr. Pharmaceutical Des.* **19** 3466–73
- [138] Loozen L D, Wegman F, Öner F C, Dhert W J A and Alblas J 2013 Porous bioprinted constructs in BMP-2 non-viral gene therapy for bone tissue engineering *J. Mater. Chem. B* **1** 6619
- [138] Lagasse E et al 2000 Purified hematopoietic stem cells can differentiate into hepatocytes *in vivo* *Nat. Med.* **6** 1229–34
- [140] Si-Tayeb K et al 2010 Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells *Hepatology* **51** 297–305
- [141] Liu T, Zhang S C, Chen X, Li G Q and Wang Y J 2010 Hepatic differentiation of mouse embryonic stem cells in three-dimensional polymer scaffolds *Tissue Eng. A* **16** 1115–22

- [142] Khetani S R and Bhatia S N 2008 Microscale culture of human liver cells for drug development *Nat. Biotechnol.* **26** 120–6
- [143] Prodanov L *et al* 2015 Long-term maintenance of a microfluidic 3D human liver sinusoid *Biotechnol. Bioeng.* **113** 241–6
- [144] Rashid S T *et al* 2010 Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells *J. Clin. Investigation* **120** 3127
- [145] Bertassoni L E *et al* 2014 Direct-write bioprinting of cell-laden methacrylated gelatin hydrogels *Biofabrication* **6** 024105
- [146] Lindenmair A *et al* 2012 Mesenchymal stem or stromal cells from amnion and umbilical cord tissue and their potential for clinical applications *Cells* **1** 1061–88
- [147] Nakao Y, Kimura H, Sakai Y and Fujii T 2011 Bile canaliculi formation by aligning rat primary hepatocytes in a microfluidic device *Biomicrofluidics* **5** 22212
- [148] Skardal A, Smith L, Bharadwaj S, Atala A, Soker S and Zhang Y 2012 Tissue specific synthetic ECM hydrogels for 3D *in vitro* maintenance of hepatocyte function *Biomaterials* **33** 4565–75
- [149] Chang R, Emami K, Wu H and Sun W 2010 Biofabrication of a three-dimensional liver micro-organ as an *in vitro* drug metabolism model *Biofabrication* **2** 045004
- [150] Cho N-J *et al* 2009 Viral infection of human progenitor and liver-derived cells encapsulated in three-dimensional PEG-based hydrogel *Biomed. Mater.* **4** 011001
- [151] Xiong A *et al* 2008 Isolation of human fetal liver progenitors and their enhanced proliferation by three-dimensional coculture with endothelial cells *Tissue Eng. A* **14** 995–1006
- [152] Tung Y-C, Hsiao A Y, Allen S G, Torisawa Y-S, Ho M and Takayama S 2011 High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array *Analyst* **136** 473–8
- [153] Justice B A, Badr N A and Felder R A 2009 3D cell culture opens new dimensions in cell-based assays *Drug Discovery Today* **14** 102–7
- [154] Fischbach C *et al* 2007 Engineering tumors with 3D scaffolds *Nat. Methods* **4** 855–60
- [155] Asghar W, El Assal R, Shafiee H, Pitteri S, Paulmurugan R and Demirci U 2015 Engineering cancer microenvironments for *in vitro* 3D tumor models *Mater. Today* **18** 539–53
- [156] Asghar W *et al* 2013 *In vitro* three-dimensional cancer culture models *Cancer Targeted Drug Delivery* (Berlin: Springer) pp 635–65
- [157] Oliveira M B, Neto A I, Correia C R, Rial-Hermida M I, Alvarez-Lorenzo C and Mano J F 2014 Superhydrophobic chips for cell spheroids high-throughput generation and drug screening *ACS Appl. Mater. Interfaces* **6** 9488–95
- [158] Friedrich J, Seidel C, Ebner R and Kunz-Schughart L A 2009 Spheroid-based drug screen: considerations and practical approach *Nat. Protocols* **4** 309–24
- [159] Chang T T and Hughes-Fulford M 2009 Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes *Tissue Eng. A* **15** 559–67
- [160] Charoen K M, Fallica B, Colson Y L, Zaman M H and Grinstaff M W 2014 Embedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug and drug-device combinations *Biomaterials* **35** 2264–71
- [161] Zhang X L *et al* 2005 Development of an *in vitro* multicellular tumor spheroid model using microencapsulation and its application in anticancer drug screening and testing *Biotechnol. Prog.* **21** 1289–96
- [162] Fong E L S *et al* 2014 Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening *Mol. Pharmaceutics* **11** 2040–50
- [163] Wu L Y, Di Carlo D and Lee L P 2008 Microfluidic self-assembly of tumor spheroids for anticancer drug discovery *Biomed. Microdevices* **10** 197–202
- [164] Buchanan C F, Voigt E E, Szot C S, Freeman J W, Vlachos P P and Rylander M N 2014 Three-dimensional microfluidic collagen hydrogels for investigating flow-mediated tumor-endothelial signaling and vascular organization *Tissue Eng. C* **20** 64–75
- [165] Arrabito G, Galati C, Castellano S and Pignataro B 2013 Luminometric sub-nanoliter droplet-to-droplet array (LUMDA) and its application to drug screening by phase I metabolism enzymes *Lab Chip* **13** 68–72
- [166] Horváth L, Umehara Y, Jud C, Blank F, Petri-Fink A and Rothen-Rutishauser B 2015 Engineering an *in vitro* air-blood barrier by 3D bioprinting *Sci. Rep.* **5** 7974
- [167] Asghar W, El Assal R, Shafiee H, Anchan R M and Demirci U 2014 Preserving human cells for regenerative, reproductive, and transfusion medicine *Biotechnol. J.* **9** 895–903
- [168] Lucena E, Bernal D P, Lucena C, Rojas A, Moran A and Lucena A S 2006 Successful ongoing pregnancies after vitrification of oocytes *Fertility Sterility* **85** 108–11
- [169] Leibo S and Pool T B 2011 The principal variables of cryopreservation: solutions, temperatures, and rate changes *Fertility Sterility* **96** 269–76
- [170] Desrosiers P, Légaré C, Ceclerc P and Sullivan R 2006 Membranous and structural damage that occur during cryopreservation of human sperm may be time-related events *Fertility Sterility* **85** 1744–52
- [171] Chen S-U and Yang Y-S 2009 Slow freezing or vitrification of oocytes: their effects on survival and meiotic spindles, and the time schedule for clinical practice *Taiwanese J. Obstetrics Gynecology* **48** 15
- [172] Guven S *et al* 2015 Functional maintenance of differentiated embryoid bodies in microfluidic systems: a platform for personalized medicine *Stem. Cells Transl. Med.* 2014–0119 (doi:10.5966/sctm.2014-0119)
- [173] Kline M, Dreyer M, Gyring P, Lifson M and El Assal R 2015 Innovative cryoprotectants for tissue and organ preservation *Cryobiology* **71** 180
- [174] Zhang X, Catalano P N, Gurkan U A, Khimji I and Demirci U 2011 Emerging technologies in medical applications of minimum volume vitrification *Nanomedicine* **6** 1115–29
- [175] Snyder J E *et al* 2011 Bioprinting cell-laden matrigel for radioprotection study of liver by pro-drug conversion in a dual-tissue microfluidic chip *Biofabrication* **3** 034112
- [176] Rupnick M A *et al* 2002 Adipose tissue mass can be regulated through the vasculature *Proc. Natl Acad. Sci. USA* **99** 10730–5
- [177] Langer R S and Vacanti J P 1999 Tissue engineering: the challenges ahead *Sci. Am.* **280** 86–9
- [178] Hutmacher D W 2001 Scaffold design and fabrication technologies for engineering tissues—state of the art and future perspectives *J. Biomater. Sci.—Polym. Ed.* **12** 107–24
- [179] Henze U, Kaufmann M, Klein B, Handt S and Klosterhalfen B 1996 Endothelium and biomaterials: morpho-functional assessments *Biomed. Pharmacotherapy* **50** 388
- [180] Dado D and Levenberg S 2009 Cell-scaffold mechanical interplay within engineered tissue *Semin. Cell Dev. Biol.* **20** 656–64
- [181] Hockaday L A *et al* 2012 Rapid 3D printing of anatomically accurate and mechanically heterogeneous aortic valve hydrogel scaffolds *Biofabrication* **4**
- [182] Mironov V, Boland T, Trusk T, Forgacs G and Markwald R R 2003 Organ printing: computer-aided jet-based 3D tissue engineering *Trends Biotechnol.* **21** 157–61
- [183] Prestwich G D 2011 Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine *J. Control. Release* **155** 193–9
- [184] Rizvi I *et al* 2013 Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules *Proc. Natl Acad. Sci.* **110** E1974–83
- [185] Luo Z *et al* 2015 Deformation of a single mouse oocyte in a constricted microfluidic channel *Microfluidics Nanofluidics* **19** 883–90
- [186] Anchan R *et al* 2015 Human iPSC-derived steroidogenic cells maintain endocrine function with extended culture in a microfluidic chip system *Fertility Sterility* **104** e73
- [187] Gurkan U A *et al* 2012 Smart interface materials integrated with microfluidics for on-demand local capture and release of cells *Adv. Healthc. Mater.* **1** 661–8
- [188] Gurkan U A *et al* 2011 Controlled viable release of selectively captured label-free cells in microchannels *Lab Chip* **11** 3979–89